🇺🇸 FDA
Patent

US 11129856

Methods of treating chronic wounds with amniotic fluid having elevated levels of tissue inhibitors of matrix metalloproteinases

granted A61KA61K35/50A61K45/06

Quick answer

US patent 11129856 (Methods of treating chronic wounds with amniotic fluid having elevated levels of tissue inhibitors of matrix metalloproteinases) held by Prime Merger Sub, LLC expires Mon Sep 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Prime Merger Sub, LLC
Grant date
Tue Sep 28 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K35/50, A61K45/06